Agios Pharmaceuticals Inc (NASDAQ:AGIO) insider Scott Biller sold 3,000 shares of the stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $83.08, for a total value of $249,240.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Scott Biller also recently made the following trade(s):
- On Monday, February 5th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $76.04, for a total value of $228,120.00.
- On Wednesday, January 10th, Scott Biller sold 3,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.00, for a total value of $195,000.00.
Shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) traded down $0.17 during trading on Wednesday, reaching $83.33. The company’s stock had a trading volume of 237,701 shares, compared to its average volume of 662,786. Agios Pharmaceuticals Inc has a 12-month low of $45.11 and a 12-month high of $85.88. The firm has a market capitalization of $4,790.00, a PE ratio of -12.36 and a beta of 2.02.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16). Agios Pharmaceuticals had a negative net margin of 731.60% and a negative return on equity of 76.67%. The firm had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. During the same period last year, the business posted ($1.34) EPS. The company’s revenue was down 56.7% on a year-over-year basis. equities analysts expect that Agios Pharmaceuticals Inc will post -6.15 earnings per share for the current year.
A number of institutional investors have recently made changes to their positions in AGIO. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Agios Pharmaceuticals by 41.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,600 shares of the biopharmaceutical company’s stock valued at $149,000 after purchasing an additional 762 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $160,000. Bank of Montreal Can lifted its holdings in shares of Agios Pharmaceuticals by 74.8% in the fourth quarter. Bank of Montreal Can now owns 3,551 shares of the biopharmaceutical company’s stock valued at $203,000 after purchasing an additional 1,520 shares in the last quarter. Teacher Retirement System of Texas bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $225,000. Finally, S&CO Inc. bought a new position in shares of Agios Pharmaceuticals in the third quarter valued at approximately $227,000. 82.40% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently commented on AGIO shares. Oppenheimer set a $83.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 17th. SunTrust Banks set a $80.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 19th. Cann reaffirmed a “buy” rating on shares of Agios Pharmaceuticals in a research note on Tuesday, December 5th. Canaccord Genuity set a $90.00 target price on Agios Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Finally, BidaskClub cut Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 16th. Four investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $85.50.
ILLEGAL ACTIVITY NOTICE: “Agios Pharmaceuticals Inc (NASDAQ:AGIO) Insider Scott Biller Sells 3,000 Shares” was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://ledgergazette.com/2018/03/14/agios-pharmaceuticals-inc-agio-insider-sells-249240-00-in-stock.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.